ARVN
Price
$7.72
Change
+$0.17 (+2.25%)
Updated
Oct 22 closing price
Capitalization
504.78M
13 days until earnings call
Intraday BUY SELL Signals
BBOT
Price
$2.85
Change
+$0.17 (+6.34%)
Updated
Oct 22 closing price
Capitalization
228.5M
20 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARVN vs BBOT

ARVN vs BBOT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARVN vs. BBOT commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a StrongBuy and BBOT is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARVN with price predictions
Oct 22, 2026

ARVN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ARVN turned positive on October 19, 2026. Looking at past instances where ARVN's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARVN's RSI Oscillator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ARVN as a result. In 71 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

Following a +9.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARVN advanced for three days, in 200 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The 10-day moving average for ARVN crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for ARVN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.898) is normal, around the industry mean (2.973). P/E Ratio (25.733) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.733) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for BBOT with price predictions
Oct 22, 2026

BBOT in +7.61% Uptrend, growing for three consecutive days on September 30, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BBOT advanced for three days, in 44 of 67 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BBOT just turned positive on October 02, 2026. Looking at past instances where BBOT's MACD turned positive, the stock continued to rise in 17 of 38 cases over the following month. The odds of a continued upward trend are 45%.

BBOT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBOT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

The Aroon Indicator for BBOT entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (2.973). P/E Ratio (-1.254) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. BBOT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBOT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ARVN: Fundamental Ratings
ARVN
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
83
PRICE GROWTH RATING
1..100
74
P/E GROWTH RATING
1..100
45
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARVNBBOT
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
N/A
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
45%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
49%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
51%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 23 days ago
66%
Declines
ODDS (%)
Bearish Trend 9 days ago
81%
Bearish Trend 2 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
54%
Aroon
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
78%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ARVN: $7.55 vs. BBOT: $2.68)
Brand notoriety: ARVN and BBOT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 80% vs. BBOT: 195%
Market capitalization -- ARVN: $504.78M vs. BBOT: $228.5M
ARVN [@Biotechnology] is valued at $504.78M. BBOT’s [@Biotechnology] market capitalization is $228.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 0 FA rating(s) are green while BBOT’s FA Score has 1 green FA rating(s).

  • ARVN’s FA Score: 0 green, 5 red.
  • BBOT’s FA Score: 1 green, 4 red.
According to our system of comparison, BBOT is a better buy in the long-term than ARVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 5 TA indicator(s) are bullish while BBOT’s TA Score has 3 bullish TA indicator(s).

  • ARVN’s TA Score: 5 bullish, 4 bearish.
  • BBOT’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, ARVN is a better buy in the short-term than BBOT.

Price Growth

ARVN (@Biotechnology) experienced а +10.78% price change this week, while BBOT (@Biotechnology) price change was -7.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ARVN is expected to report earnings on Nov 04, 2026.

BBOT is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARVN
Daily Signal:
Gain/Loss:
BBOT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
+2.18%
AXON - ARVN
46%
Loosely correlated
+2.98%
VCYT - ARVN
46%
Loosely correlated
-0.39%
STOK - ARVN
46%
Loosely correlated
+0.08%
KURA - ARVN
46%
Loosely correlated
-0.20%
XNCR - ARVN
45%
Loosely correlated
+2.70%
More

BBOT and

Correlation & Price change

A.I.dvisor indicates that over the last year, BBOT has been loosely correlated with MLTX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if BBOT jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBOT
1D Price
Change %
BBOT100%
+6.34%
MLTX - BBOT
37%
Loosely correlated
+15.87%
LXEO - BBOT
36%
Loosely correlated
-3.67%
IMNM - BBOT
36%
Loosely correlated
+1.44%
NKTX - BBOT
34%
Loosely correlated
-0.57%
MIST - BBOT
34%
Loosely correlated
+1.06%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GPRF47.75-0.03
-0.05%
Goldman Sachs Access U.S. Preferred Stock and Hybrid Securities ETF (GPRF)
CPSA28.20-0.03
-0.11%
Calamos S&P 500 Structured Alt Protection ETF August (CPSA)
EKG23.89-0.14
-0.59%
First Trust Nasdaq Lux Digital Health Solutions ETF (EKG)
KMLM30.48-0.36
-1.17%
KraneShares Mount Lucas Managed Futures Index Strategy ETF (KMLM)
GNR75.12-1.26
-1.65%
State Street SPDR S&P Global Natural Resources ETF (GNR)